Seized drugs

This workshop explores the impact inconsistent drug analysis reporting has on public health and public trust. The value and implementation of the Global Uniform Analysis and Reporting of Drug-Related Substances (GUARDS) innovative methodology in over 200 instruments across United States Drug Enforcement Administration (DEA) laboratories are presented, as well as the efforts of other labs of the U.S. Customs and Border Protection (CBP) and Illinois State Police.

Of recent, forensic toxicology laboratories have been grappling with the emergence of tetrahydrocannabinol isomers within biological specimens. Traditional methodologies are often inadequate in the separation of Δ9-tetrahydrocannabinol and Δ8-tetrahydrocannabinol, which are the most common isomers identified in forensic testing.

With the passage of the 2018 Agricultural Improvement Act (Farm Bill), forensic laboratories have been tasked with differentiating seized cannabis samples as either hemp or marijuana. The new legislation declassified hemp as a Schedule 1 drug substance and defined it as cannabis containing 0.3 % or less of decarboxylated-Δ9-THC (total Δ9-THC). The National Institute of Standards and Technology (NIST) has been working to help forensic laboratories with these challenging measurements through the development of extraction protocols and analytical methods.

As evident by the Cannabinoid Connundrums webinar series, the rapidly changing world of cannabinoids offers many conundrums. To tackle some of these questions, Dr. Ruth Winecker led a panel discussion with Dr. Ed Cone, Dr. Nathalie Desrosiers, Mr. Justin Poklis, and Mr. Nelson Santos. This diverse slate of thought leaders includes experts in analytical chemistry, forensic toxicology, clinical research, and drug chemistry. This webinar was hosted by the NIJ Forensic Technology Center of Excellence on August 3, 2023. 

Controlled drug administration studies are valuable tools for acquiring a detailed understanding of the pharmacodynamic and pharmacokinetic profiles of cannabinoids. ∆9-tetrahydrocannabinoid (THC) is the primary psychoactive cannabinoid in cannabis with the potential to negatively impact cognitive and psychomotor performance and workplace safety. These studies establish behavioral and subjective effect profiles while simultaneously collecting pharmacokinetics data.

THC isomers, also known as THC analogs or semi-synthetic cannabinoids, are structurally related to Δ9-tetrahydrocannabinol (Δ9-THC) and have similar toxicity and impairing effects. A recent study indicated that Δ8-THC use was around 27% of marijuana use, based on detection and ratios of cannabinoid metabolites in workplace drug testing. Other analogs of interest include hexahydrocannabinol (HHC) and THC-O. THC isomers are generally perceived as legal and are also seen in states with legal marijuana.